Toujeo (previously Optisulin)

RSS

insulin glargine

Authorised
This medicine is authorised for use in the European Union.

Overview

Toujeo is a medicine used to control blood glucose (sugar) levels in adults and children from 6 years of age who have diabetes and need insulin.

It contains the active substance insulin glargine.

This EPAR was last updated on 11/04/2022

Authorisation details

Product details
Name
Toujeo (previously Optisulin)
Agency product number
EMEA/H/C/000309
Active substance
insulin glargine
International non-proprietary name (INN) or common name
insulin glargine
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AE04
Publication details
Marketing-authorisation holder
Sanofi-aventis Deutschland GmbH
Revision
32
Date of issue of marketing authorisation valid throughout the European Union
26/06/2000
Contact address
D-65926 Frankfurt am Main
Germany

Product information

26/11/2021 Toujeo (previously Optisulin) - EMEA/H/C/000309 - N/0118

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
2 ratings